PMID- 38370161
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240220
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 11
DP  - 2024
TI  - Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors 
      and angiogenesis inhibitors: a meta-analysis.
PG  - 1309100
LID - 10.3389/fcvm.2024.1309100 [doi]
LID - 1309100
AB  - INTRODUCTION: Combinations of immune checkpoint inhibitors (ICIs) and 
      angiogenesis inhibitors (AIs) have been investigated for the treatment of several 
      tumor types. Both ICIs and AIs may lead to cardiovascular adverse events, and 
      their combination may potentially increase the risk for cardiovascular toxicity. 
      In the present meta-analysis, we aim to assess the cardiovascular toxicity of 
      ICIs plus AIs vs. AIs alone. Secondary objectives are non-cardiovascular adverse 
      events and efficacy. METHODS: Systematic review was performed according to PRISMA 
      statement. Phase II and III randomized clinical trials were identified by 
      searching the MEDLINE/PubMed, Cochrane Library and ASCO Meeting abstracts, from 
      inception to June 2022. The pooled risks for overall response rate (ORR), 1-year 
      progression-free survival (PFS), adverse events (AEs), immune-related AEs, 
      (irAEs), hypertension, and vascular events defined as stroke, myocardial 
      infarction and pulmonary embolisms, were calculated. RESULTS: In terms of 
      cardiovascular toxicity, we found higher risk for severe hypertension among 
      patients treated with ICIs plus AIs as compared with those receiving AIs (OR 
      1.24, 95% CI: 1.01-1.53), but no significant difference was found for any-grade 
      hypertension, and for vascular events. There was also no difference in terms of 
      overall AEs, whereas the incidence of irAEs was increased in the ICIs plus AIs 
      arm, as expected. In terms of efficacy, ICIs plus AIs achieved better ORR (OR 
      2.25, 95% CI: 1.70-2.97) and PFS (HR 0.49, 95% CI: 0.39-0.63) as compared to AIs 
      alone. CONCLUSION: The addition of ICIs to AIs significantly increased the risk 
      of high-grade hypertension, but not that of acute vascular events.
CI  - (c) 2024 Inno, Veccia, Madonia, Berti, Bortolotti, Incorvaia, Russo, Caffo and 
      Gori.
FAU - Inno, Alessandro
AU  - Inno A
AD  - Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di 
      Valpolicella, Italy.
FAU - Veccia, Antonello
AU  - Veccia A
AD  - Medical Oncology, Santa Chiara Hospital, Trento, Italy.
FAU - Madonia, Giorgio
AU  - Madonia G
AD  - Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di 
      Valpolicella, Italy.
AD  - Deparment of Surgical, Oncological and Oral Sciences, Section of Medical 
      Oncology, University of Palermo, Palermo, Italy.
FAU - Berti, Alvise
AU  - Berti A
AD  - Center for Medical Sciences (CISMed), Department of Cellular, Computational and 
      Integrative Biology (CIBIO), University of Trento, Trento, Italy.
AD  - Rheumatology Unit, Santa Chiara Hospital, APSS, Trento, Italy.
FAU - Bortolotti, Roberto
AU  - Bortolotti R
AD  - Rheumatology Unit, Santa Chiara Hospital, APSS, Trento, Italy.
FAU - Incorvaia, Lorena
AU  - Incorvaia L
AD  - Deparment of Surgical, Oncological and Oral Sciences, Section of Medical 
      Oncology, University of Palermo, Palermo, Italy.
FAU - Russo, Antonio
AU  - Russo A
AD  - Deparment of Surgical, Oncological and Oral Sciences, Section of Medical 
      Oncology, University of Palermo, Palermo, Italy.
FAU - Caffo, Orazio
AU  - Caffo O
AD  - Medical Oncology, Santa Chiara Hospital, Trento, Italy.
FAU - Gori, Stefania
AU  - Gori S
AD  - Medical Oncology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di 
      Valpolicella, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240202
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC10869562
OTO - NOTNLM
OT  - angiogenesis inhibitors
OT  - cardiovascular toxicity
OT  - hypertension
OT  - immune checkpoint inhibitors
OT  - multikinase inhibitors
OT  - myocardial infarction
OT  - pulmonary embolism
OT  - stroke
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The author(s) declared that they were an editorial board 
      member of Frontiers, at the time of submission. This had no impact on the peer 
      review process and the final decision.
EDAT- 2024/02/19 06:43
MHDA- 2024/02/19 06:44
PMCR- 2024/01/01
CRDT- 2024/02/19 04:07
PHST- 2023/10/07 00:00 [received]
PHST- 2024/01/22 00:00 [accepted]
PHST- 2024/02/19 06:44 [medline]
PHST- 2024/02/19 06:43 [pubmed]
PHST- 2024/02/19 04:07 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2024.1309100 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2024 Feb 2;11:1309100. doi: 10.3389/fcvm.2024.1309100. 
      eCollection 2024.